A carregar...
Development of EGFR TKIs and Options to Manage Resistance of Third-Generation EGFR TKI Osimertinib: Conventional Ways and Immune Checkpoint Inhibitors
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) have been first-line therapy in the treatment of non-small cell lung cancer (NSCLC) harboring EGFR sensitive mutations. Progression inevitably happens after 10–14 months of first- or second-generation EGFR TKIs treatment for acq...
Na minha lista:
| Publicado no: | Front Oncol |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Frontiers Media S.A.
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7775519/ https://ncbi.nlm.nih.gov/pubmed/33392095 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2020.602762 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|